AbbVie dodged a patent disaster, and shares gained 460%. Merck and Bristol Myers are next.

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Keytruda Market Size to Hit USD 71.07 Billion by 2033, Driven by Expanding Immuno-Oncology Adoption – SNS Insider

Rising clinical innovations, combination therapy advances, and growing cancer prevalence accelerate global and U.S. market growth.Austin, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Keytruda Market Size ...
BioSpace

JPM26: Confident Merck Sees Growth Through Keytruda Loss of Exclusivity

Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the company is open to deals in the range of “multi tens of billions of dollars.” ...
Oncology Nurse Advisor

FDA Approves Padcev for Muscle-Invasive Bladder Cancer

Approval is for combination use with pembrolizumab both before and after surgery. HealthDay News — The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv), a Nectin-4 ...
Seeking Alpha

Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining ...